ExploreWatchlistsPricing
  1. JP-listed companies
  2. SEIKAGAKU CORPORATION
  3. Financials
  4. Pretax margin (%)

SEIKAGAKU CORPORATION (4548)

Market cap
¥44.8B
P/E ratio
19.2x
Develops and manufactures pharmaceuticals for joint care, eye surgery, and spinal treatments, plus specialized LAL testing reagents that ensure drug safety.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndPretax margin (%) YoY (%)
Mar 31, 20264.6-6.67%
Mar 31, 20254.9+5.13%
Mar 31, 20244.7-49.10%
Mar 31, 20239.2-40.74%
Mar 31, 202215.5+41.60%
Mar 31, 202110.9-21.35%
Mar 31, 202013.9+37.99%
Mar 31, 201910.1-42.94%
Mar 31, 201817.7+110.88%
Mar 31, 20178.4-25.94%
Mar 31, 201611.3-16.74%
Mar 31, 201513.6-31.60%
Mar 31, 201419.8+22.91%
Mar 31, 201316.1-8.31%
Mar 31, 201217.6

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat